Drug Profile
BMS 791826
Alternative Names: BMS-791826Latest Information Update: 28 Feb 2019
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class Anti-inflammatories; Pyridines; Small molecules; Thiadiazoles; Xanthenes
- Mechanism of Action Glucocorticoid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Immunological disorders
Most Recent Events
- 28 Feb 2019 No recent reports of development identified for phase-I development in Immunological-disorders(In volunteers) in Australia
- 31 Jul 2017 Chemical structure information added